GRTS Live signals | Maximize Profits with Getagraph.com

BUY 94471 min ago

@ $2.18

Issued: 14 Feb 2024 @ 14:06

Return: -66.13%

Previous signal: Feb 13 - 15:42

Previous signal: Sell

Return: 3.82 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases...

Stats
Today's Volume	1.52M
Average Volume	2.90M
Market Cap	78.37M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.300 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.610
ATR14	$0.00300 (0.41%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-01	Hawryluk Matthew	Buy	35 000	Common Stock
2024-02-01	Hawryluk Matthew	Buy	180 000	Stock Option (Right to Buy)
2024-02-01	Jones Erin	Buy	40 000	Common Stock
2024-02-01	Jones Erin	Buy	235 000	Stock Option (Right to Buy)
2024-02-01	Economides Vassiliki	Buy	35 000	Common Stock

INSIDER POWER
100.00
Last 97 transactions
Buy: 5 929 842 \| Sell: 139 571

Volume Correlation

Long: -0.10 (neutral)

Short: 0.51 (weak)

Signal:(69.396) Neutral

Gritstone Oncology Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gritstone Oncology Inc Correlation - Currency/Commodity

-0.36
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.08
( neutral )

-0.38
( neutral )

Gritstone Oncology Inc Financials

Annual	2023
Revenue:	$1.33M
Gross Profit:	$-6.26M (-470.32 %)
EPS:	$-1.200

Q4	2023
Revenue:	$29 000.00
Gross Profit:	$-1.89M (-6 524.14 %)
EPS:	$-0.320

Q3	2023
Revenue:	$1.57M
Gross Profit:	$-399 000 (-25.50 %)
EPS:	$-0.330

Q2	2023
Revenue:	$400 000
Gross Profit:	$-1.23M (-307.75 %)
EPS:	$-0.310

Financial Reports:

No articles found.

Gritstone Oncology Inc

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.